Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Hung Fang

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
ACS Applied Materials & Interfaces|April 10, 2023
Dual-Ion Co-intercalation Mechanism on a Na<sub>2</sub>V<sub>6</sub>O<sub>16</sub>·3H<sub>2</sub>O Cathode with a Commercial-Level Mass Loading for Aqueous Zinc-Ion Batteries with High Areal CapacityFeiran Gong, Yichen Feng, Yu-Hung Fang, et al.
Oncotargets and Therapy|January 4, 2023
Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated <i>Clostridioides difficile</i> Infection Among Patients with Lung CancerYing-Shan Chung, Yu-Ching Lin, Ming-Szu Hung, et al.
Cancer Management and Research|October 2, 2019
Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based studyYu-Hung Fang, Yao-Hsu Yang, Meng-Jer Hsieh, et al.
Oncotargets and Therapy|January 4, 2023
Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung CancerMeng-Chin Ho, Ying-Shan Chung, Yu-Ching Lin, et al.
Diagnostics (Basel, Switzerland)|May 24, 2024
Spheroids Generated from Malignant Pleural Effusion as a Tool to Predict the Response of Non-Small Cell Lung Cancer to TreatmentTsung-Ming Yang, Yu-Hung Fang, Chieh-Mo Lin, et al.
BMC Cancer|April 15, 2024
The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarkerJia-Rong Wu, Vincent Chin-Hung Chen, Yu-Hung Fang, et al.
Molecular and Clinical Oncology|February 20, 2018
Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common <i>EGFR</i> mutationsMing-Szu Hung, Yu-Hung Fang, Yu-Ching Lin, et al.
Oncotargets and Therapy|November 11, 2017
Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancerYu-Hung Fang, Chien-Chin Hsu, Meng-Jer Hsieh, et al.
Medicine|July 2, 2016
The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutationsMing-Szu Hung, Jr-Hau Lung, Yu-Ching Lin, et al.
Cancer Management and Research|June 24, 2021
Sleep Quality and Related Factors in Patients with Breast Cancer: A Cross-Sectional Study in TaiwanYi-Ping Weng, Rei-Mei Hong, Vincent Chin-Hung Chen, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
ACS Applied Materials & Interfaces|April 10, 2023
Dual-Ion Co-intercalation Mechanism on a Na<sub>2</sub>V<sub>6</sub>O<sub>16</sub>·3H<sub>2</sub>O Cathode with a Commercial-Level Mass Loading for Aqueous Zinc-Ion Batteries with High Areal CapacityFeiran Gong, Yichen Feng, Yu-Hung Fang, et al.
Oncotargets and Therapy|January 4, 2023
Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated <i>Clostridioides difficile</i> Infection Among Patients with Lung CancerYing-Shan Chung, Yu-Ching Lin, Ming-Szu Hung, et al.
Cancer Management and Research|October 2, 2019
Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based studyYu-Hung Fang, Yao-Hsu Yang, Meng-Jer Hsieh, et al.
Oncotargets and Therapy|January 4, 2023
Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung CancerMeng-Chin Ho, Ying-Shan Chung, Yu-Ching Lin, et al.
Diagnostics (Basel, Switzerland)|May 24, 2024
Spheroids Generated from Malignant Pleural Effusion as a Tool to Predict the Response of Non-Small Cell Lung Cancer to TreatmentTsung-Ming Yang, Yu-Hung Fang, Chieh-Mo Lin, et al.
BMC Cancer|April 15, 2024
The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarkerJia-Rong Wu, Vincent Chin-Hung Chen, Yu-Hung Fang, et al.
Molecular and Clinical Oncology|February 20, 2018
Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common <i>EGFR</i> mutationsMing-Szu Hung, Yu-Hung Fang, Yu-Ching Lin, et al.
Oncotargets and Therapy|November 11, 2017
Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancerYu-Hung Fang, Chien-Chin Hsu, Meng-Jer Hsieh, et al.
Medicine|July 2, 2016
The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutationsMing-Szu Hung, Jr-Hau Lung, Yu-Ching Lin, et al.
Cancer Management and Research|June 24, 2021
Sleep Quality and Related Factors in Patients with Breast Cancer: A Cross-Sectional Study in TaiwanYi-Ping Weng, Rei-Mei Hong, Vincent Chin-Hung Chen, et al.
Pageof 3